New Strong Buy Stocks for May 28th

By Zacks Equity Research | May 28, 2025, 4:37 AM

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

Phio Pharmaceuticals PHIO: This company which is focused on developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform, has seen the Zacks Consensus Estimate for its current year earnings increasing 14.4% over the last 60 days.

Phio Pharmaceuticals Corp. Price and Consensus

Phio Pharmaceuticals Corp. Price and Consensus

Phio Pharmaceuticals Corp. price-consensus-chart | Phio Pharmaceuticals Corp. Quote

Flex LNG FLNG: This shipping company which is focused on transportation of liquefied natural gas, has seen the Zacks Consensus Estimate for its current year earnings increasing 12.1% over the last 60 days.

Flex LNG Ltd. Price and Consensus

Flex LNG Ltd. Price and Consensus

Flex LNG Ltd. price-consensus-chart | Flex LNG Ltd. Quote

Bridgewater Bancshares BWB: This bank holding company which provides personal and commercial banking products and services to commercial real estate investors, small business entrepreneurs and high-net-worth individuals, has seen the Zacks Consensus Estimate for its current year earnings increasing 11.7% over the last 60 days.

Bridgewater Bancshares, Inc. Price and Consensus

Bridgewater Bancshares, Inc. Price and Consensus

Bridgewater Bancshares, Inc. price-consensus-chart | Bridgewater Bancshares, Inc. Quote

Alerus Financial ALRS: This financial services company, which offers banking, retirement and benefit services, wealth management and mortgage to businesses and consumers, has seen the Zacks Consensus Estimate for its current year earnings increasing 6.1% over the last 60 day.

Alerus Financial Price and Consensus

Alerus Financial Price and Consensus

Alerus Financial price-consensus-chart | Alerus Financial Quote

Halozyme Therapeutics HALO: This biopharmaceutical company which is focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment, has seen the Zacks Consensus Estimate for its current year earnings increasing 4.4% over the last 60 days.

Halozyme Therapeutics, Inc. Price and Consensus

Halozyme Therapeutics, Inc. Price and Consensus

Halozyme Therapeutics, Inc. price-consensus-chart | Halozyme Therapeutics, Inc. Quote

 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
 
Bridgewater Bancshares, Inc. (BWB): Free Stock Analysis Report
 
Phio Pharmaceuticals Corp. (PHIO): Free Stock Analysis Report
 
Flex LNG Ltd. (FLNG): Free Stock Analysis Report
 
Alerus Financial (ALRS): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Latest News